1. Home
  2. NNNN vs SUPN Comparison

NNNN vs SUPN Comparison

Compare NNNN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNNN
  • SUPN
  • Stock Information
  • Founded
  • NNNN 2021
  • SUPN 2005
  • Country
  • NNNN Germany
  • SUPN United States
  • Employees
  • NNNN N/A
  • SUPN N/A
  • Industry
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • NNNN Health Care
  • SUPN Health Care
  • Exchange
  • NNNN Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • NNNN 2.2B
  • SUPN 2.6B
  • IPO Year
  • NNNN 2025
  • SUPN 2012
  • Fundamental
  • Price
  • NNNN $27.36
  • SUPN $44.75
  • Analyst Decision
  • NNNN
  • SUPN Strong Buy
  • Analyst Count
  • NNNN 0
  • SUPN 4
  • Target Price
  • NNNN N/A
  • SUPN $63.25
  • AVG Volume (30 Days)
  • NNNN 39.8K
  • SUPN 1.1M
  • Earning Date
  • NNNN 04-28-2026
  • SUPN 11-04-2025
  • Dividend Yield
  • NNNN N/A
  • SUPN N/A
  • EPS Growth
  • NNNN N/A
  • SUPN N/A
  • EPS
  • NNNN 0.06
  • SUPN N/A
  • Revenue
  • NNNN $8,185,146.00
  • SUPN $681,539,000.00
  • Revenue This Year
  • NNNN N/A
  • SUPN $8.29
  • Revenue Next Year
  • NNNN N/A
  • SUPN $22.72
  • P/E Ratio
  • NNNN $503.50
  • SUPN N/A
  • Revenue Growth
  • NNNN 21.95
  • SUPN 4.54
  • 52 Week Low
  • NNNN $5.18
  • SUPN $29.16
  • 52 Week High
  • NNNN $55.65
  • SUPN $57.65
  • Technical
  • Relative Strength Index (RSI)
  • NNNN 54.26
  • SUPN 38.55
  • Support Level
  • NNNN $12.93
  • SUPN $44.22
  • Resistance Level
  • NNNN $25.20
  • SUPN $45.96
  • Average True Range (ATR)
  • NNNN 4.99
  • SUPN 2.46
  • MACD
  • NNNN 1.61
  • SUPN -0.86
  • Stochastic Oscillator
  • NNNN 73.40
  • SUPN 14.92

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: